scholarly journals Phytoestrogens in treatment of climacteric syndrome as an alternative to menopausal hormone therapy

2020 ◽  
Author(s):  
M. I. Mazitova ◽  
I. R. Talipova ◽  
R. R. Mardieva
Keyword(s):  
Hormone Therapy ◽  
Cardiovascular System ◽  
Postmenopausal Women ◽  
Menopausal Hormone Therapy ◽  
International Literature ◽  
Climacteric Syndrome ◽  
Sexual Symptoms ◽  
Age Related ◽  
Plant Compounds ◽  
Age Related Changes

Russian and international literature over the last 5 years was observed to study the use of phytoestrogens in treatment of climacteric syndrome. Effects of isoflavones as the main group of phytoestrogens on vasomotor, cognitive, psychological, urogenital and sexual symptoms as well as their action on the cardiovascular system, bones, and metabolic age-related changes are considered. Phytoestrogens administration is concluded to be perspective as an alternative to menopausal hormone therapy. It is reasonable to conduct further extensive researches to evaluate the effectiveness and safety of the use of the plant compounds in postmenopausal women.

The role of orexin A in pathophysiological mechanisms of sleep disorder in postmenopausal women

GYNECOLOGY ◽  
2020 ◽  
Vol 22 (1) ◽  
pp. 50-54
Author(s):  
Zukhra Kh. Ebzieva ◽  
Svetlana V. Yureneva ◽  
Tatiana Yu. Ivanets
Keyword(s):  
Hormone Therapy ◽  
Sleep Disorder ◽  
Postmenopausal Women ◽  
Menopausal Hormone Therapy ◽  
Reproductive Age ◽  
Vasomotor Symptoms ◽  
Women Of Reproductive Age ◽  
Orexin A ◽  
Group 1

Aim. To conduct a comparative analysis of serum orexin A levels in women of different age periods with and without sleep disorder and vasomotor symptoms. To evaluate the dynamics of orexin A levels under menopausal hormone therapy. Materials and methods. The study included 50 postmenopausal women and 30 women of reproductive age with a regular menstrual cycle. Using block randomization, patients are divided into 3 groups: group 1 (main group), n=25, -STRAW+ 10 (+1b and +1c), patients with sleep disorder and vasomotor symptoms; group 2 (comparison group), n=25, STRAW+ 10 (+1b and +1c), patients with vasomotor symptoms without sleep disorder; group 3 (control group), n=30, STRAW+ 10 (-4), women of reproductive age without sleep disorder. Group 1 patients were given menopausal hormone therapy. A comparative analysis was carried out using the questionnaire for assessing menopausal symptoms severity by the Greene Scale (the Greene Climacteric Scale) and Rating Scale for subjective sleep characteristics. After 12 weeks of treatment, a control examination was performed. Results. In group 1 women, the serum orexin A levels were significantly higher compared to the women without the symptoms. The link between the orexin A levels and menopause syndrome severity was established. A significant decrease in the menopausal symptoms severity after 12 weeks of menopausal hormone therapy was shown. It was accompanied by a 1,3-fold decrease in orexin A levels. Conclusions. The obtained data indicate the possible role of orexin A and the orexin neuropeptide system in the pathogenesis of sleep disorder and vasomotor symptoms in postmenopausal women.

scholarly journals Body fat distribution, menopausal hormone therapy and incident type 2 diabetes in postmenopausal women of the MESA study

Maturitas ◽  
2016 ◽  
Vol 91 ◽  
pp. 147-152
Author(s):  
Imo A. Ebong ◽  
Karol E. Watson ◽  
Kristen G. Hairston ◽  
Mercedes R. Carnethon ◽  
Pamela Ouyang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Hormone Therapy ◽  
Postmenopausal Women ◽  
Body Fat ◽  
Fat Distribution ◽  
Body Fat Distribution ◽  
Menopausal Hormone Therapy ◽  
Incident Type ◽  
Incident Type 2 Diabetes

Effects of menopausal hormone therapy on cardiovascular diseases and type 2 diabetes in middle-aged postmenopausal women

Menopause ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Ji-Eun Kim ◽  
Jaesung Choi ◽  
JooYong Park ◽  
Aesun Shin ◽  
Nam-Kyong Choi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Diseases ◽  
Hormone Therapy ◽  
Postmenopausal Women ◽  
Menopausal Hormone Therapy ◽  
Middle Aged

scholarly journals Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer

2010 ◽  
Vol 126 (3) ◽  
pp. 749-761 ◽  
Author(s):  
Kerryn W. Reding ◽  
David R. Doody ◽  
Anne McTiernan ◽  
Li Hsu ◽  
Scott Davis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Menopausal Hormone Therapy ◽  
Related Variation ◽  
Age Related ◽  
The Relationship

Ultrasound parameters of pelvic organs and their age-related changes in a cohort of asymptomatic postmenopausal women: A community-based study

2020 ◽  
Vol 26 (3) ◽  
pp. 147-154
Author(s):  
Thiran D Dias ◽  
Thilina S Palihawadana ◽  
Malitha Patabendige ◽  
Mary BC Motha ◽  
Hithanadura J de Silva
Keyword(s):  
Postmenopausal Women ◽  
Endometrial Thickness ◽  
Hormone Replacement ◽  
Sri Lankan ◽  
Community Based ◽  
Pelvic Organs ◽  
Age Related ◽  
Pelvic Ultrasonography ◽  
Ultrasound Parameters ◽  
Age Related Changes

Objective To describe the ultrasound parameters of pelvic organs and their age-related changes in a cohort of asymptomatic postmenopausal women and to describe the prevalence of ultrasound-detected pathologies in a Sri Lankan population. Study design A large community-based longitudinal study using a randomly selected sample of postmenopausal women who have never used hormone replacement therapy. Main outcome measures Uterine, endometrial and ovarian measurements at pelvic ultrasonography as described by the International Endometrial Tumor Analysis and the International Ovarian Tumor Analysis groups. Results A total of 815 postmenopausal women were approached and all volunteered to participate. This included women between the ages of 45 and 74 years with a median (interquartile range (IQR)) of 62.0 (10.0) years. The median (IQR) uterine volume was 18.1 (17) ml, while the median (IQR) of right and left ovarian volumes were 17.3 (22.9) ml and 18.2 (21.5) ml. Both uterine and ovarian volumes showed an age-related decline (p < 0.01). Furthermore, the ovarian volumes demonstrated an increase in size with a higher body mass index (p < 0.03 for left and p < 0.01 for right, respectively). Median (IQR) endometrial thickness among the population was 3.0 (1.0) mm and there was no age-related change observed. Sixty-one women had an ultrasound-detected gynaecological pathology with a prevalence of 7.5% (95% confidence interval (CI) 5.6–9.5). Conclusions This study aimed at describing ultrasound parameters of pelvic organs among postmenopausal women of Sri Lanka was able to provide the reference values for uterine and ovarian volume among asymptomatic postmenopausal women. Both uterine and ovarian volumes demonstrated an age-related decline, whereas the endometrial thickness does not seem to relate to the age.

Review Article: Sexuality and Risk-Reducing Salpingo-oophorectomy

2017 ◽  
Vol 27 (4) ◽  
pp. 847-852 ◽  
Author(s):  
Paige E. Tucker ◽  
Paul A. Cohen
Keyword(s):  
Ovarian Cancer ◽  
Hormone Therapy ◽  
Familial Cancer ◽  
Safety Data ◽  
Well Being ◽  
Menopausal Hormone Therapy ◽  
Brca1 And Brca2 ◽  
Sexual Symptoms ◽  
Increased Risk ◽  
Risk Reducing

IntroductionWomen with familial cancer syndromes such as hereditary breast and ovarian cancer syndrome (BRCA1 and BRCA2) and Lynch syndrome are at a significantly increased risk of developing ovarian cancer and are advised to undergo prophylactic removal of their ovaries and fallopian tubes at age 35 to 40 years, after childbearing is complete.MethodsA comprehensive literature search of studies on risk-reducing salpingo-oophorectomy (RRSO), sexuality, and associated issues was conducted in MEDLINE databases.ResultsRisk-reducing salpingo-oophorectomy can significantly impact on a woman’s psychological and sexual well-being, with women wishing they had received more information about this prior to undergoing surgery. The most commonly reported sexual symptoms experienced are vaginal dryness and reduced libido. Women who are premenopausal at the time of surgery may experience a greater decline in sexual function, with menopausal hormone therapy improving but not alleviating sexual symptoms. Pharmacological treatments including testosterone patches and flibanserin are available but have limited safety data in this group.ConclusionsDespite the high rates of sexual difficulties after RRSO, patient satisfaction with the decision to undergo surgery remains high. Preoperative counseling with women who are considering RRSO should include discussion of its potential sexual effects and the limitations of menopausal hormone therapy in managing symptoms of surgical menopause.

Sign in / Sign up

Export Citation Format

Share Document